Cytochrome P450 2C19 Polymorphism and Antiplatelet Therapy. Who Should Really be Genotyped?

被引：4

作者：

Kassimis, George ^{[1
]}

Stavrou, Eleana F. ^{[2
]}

Alexopoulos, Dimitrios ^{[1
]}

Athanassiadou, Aglaia ^{[2
]}

机构：

[1] Patras Univ Hosp, Dept Cardiol, Patras 26500, Greece

[2] Univ Patras, Sch Med, Lab Gen Biol, GR-26110 Patras, Greece

来源：

CURRENT PHARMACEUTICAL DESIGN | 2013年 / 19卷 / 13期

关键词：

Clopidogrel; prasugrel; ticagrelor; percutaneous coronary intervention; CYP2C19; polymorphism; CLOPIDOGREL PLATELET REACTIVITY; CORONARY-ARTERY-DISEASE; PROTON PUMP INHIBITORS; OF-FUNCTION POLYMORPHISM; MAINTENANCE-DOSE CLOPIDOGREL; ACUTE MYOCARDIAL-INFARCTION; ADVERSE CLINICAL-OUTCOMES; CALCIUM-CHANNEL BLOCKERS; ASPIRIN-TREATED PATIENTS; TIMI; 38; TRIAL;

D O I：

10.2174/1381612811319130017

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

CYP2C19 is one of the principal enzymes involved in the metabolism of clopidogrel. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function. A loss-of-function allele, CYP2C19*2, is associated with an increased risk of major adverse cardiovascular events, particularly stent thrombosis, in patients with acute coronary syndromes who are receiving clopidogrel, especially among those undergoing percutaneous coronary intervention. Newer, more potent P2Y12 inhibitors like prasugrel and ticagrelor have been introduced recently in the daily clinical practice with better cardiovascular outcome in these patients. The purpose of this review article is to provide information regarding the clinical use of CYP2C19 genotyping in patients requiring antiplatelet therapy.

引用

页码：2489 / 2495

页数：7

共 107 条

[1] Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity [J].

Alexopoulos, D. ;

Panagiotou, A. ;

Xanthopoulou, I. ;

Komninakis, D. ;

Kassimis, G. ;

Davlouros, P. ;

Fourtounas, C. ;

Goumenos, D. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (12) :2379-2385

[2] Ticagrelor Versus Prasugrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Following Percutaneous Coronary Intervention A Pharmacodynamic Study [J].

Alexopoulos, Dimitrios ;

Galati, Anastasia ;

Xanthopoulou, Ioanna ;

Mavronasiou, Eleni ;

Kassimis, George ;

Theodoropoulos, Konstantinos C. ;

Makris, George ;

Damelou, Anastasia ;

Tsigkas, Grigorios ;

Hahalis, George ;

Davlouros, Periklis .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (03) :193-199

[3] Prevalence of contraindications and conditions for precaution for prasugrel administration in a real world acute coronary syndrome population [J].

Alexopoulos, Dimitrios ;

Xanthopoulou, Ioanna ;

Mylona, Panagiota ;

Perperis, Angelos ;

Panagiotou, Aggeliki ;

Dimitropoulos, Gerasimos ;

Tsigkas, Grigorios ;

Hahalis, George ;

Davlouros, Periklis .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 32 (03) :328-333

[4] Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel The Importance of CYP2C19*2 Genotyping [J].

Alexopoulos, Dimitrios ;

Dimitropoulos, Gerasimos ;

Davlouros, Periklis ;

Xanthopoulou, Ioanna ;

Kassimis, George ;

Stavrou, Eleana F. ;

Hahalis, George ;

Athanassiadou, Aglaia .

JACC-CARDIOVASCULAR INTERVENTIONS, 2011, 4 (04) :403-410

[5] Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment [J].

Angiolillo, DJ ;

Fernandez-Ortiz, A ;

Bernardo, E ;

Ramírez, C ;

Sabaté, M ;

Jimenez-Quevedo, P ;

Hernández, R ;

Moreno, R ;

Escaned, J ;

Alfonso, F ;

Bañuelos, C ;

Costa, MA ;

Bass, TA ;

Macaya, C .

DIABETES, 2005, 54 (08) :2430-2435

[6] Variability in individual responsiveness to clopidogrel - Clinical implications, management, and future perspectives [J].

Angiolillo, Dominick J. ;

Fernandez-Ortiz, Antonio ;

Bernardo, Esther ;

Alfonso, Fernando ;

Macaya, Carlos ;

Bass, Theodore A. ;

Costa, Marco A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (14) :1505-1516

[7]

Angiolillo Dominick J, 2004, J Invasive Cardiol, V16, P169

[8] Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis [J].

Bauer, Tim ;

Bouman, Heleen J. ;

van Werkum, Jochem W. ;

Ford, Neville F. ;

ten Berg, Jurrien M. ;

Taubert, Dirk .

BMJ-BRITISH MEDICAL JOURNAL, 2011, 343

[9] Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease [J].

Berger, Jeffrey S. ;

Bhatt, Deepak L. ;

Steinhubl, Steven R. ;

Shao, Mingyuan ;

Steg, P. Gabriel ;

Montalescot, Gilles ;

Hacke, Werner ;

Fox, Keith A. ;

Lincoff, A. Michael ;

Topol, Eric J. ;

Berger, Peter B. .

CIRCULATION, 2009, 120 (23) :2337-2344

[10] Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment [J].

Bernlochner, Isabell ;

Steinhubl, Steven ;

Braun, Siegmund ;

Morath, Tanja ;

Jaitner, Juliane ;

Stegherr, Julia ;

Mehilli, Julinda ;

von Beckerath, Nicolas ;

Schoemig, Albert ;

Kastrati, Adnan ;

Sibbing, Dirk .

THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) :1193-1200

← 1 2 3 4 5 6 7 8 9 10 →